Odyssey Therapeutics, Inc.ODTX

Odyssey Therapeutics’ most recent SEC filings read like a startup’s apology letter written in red ink: in the three months to 31 March 2026, the clinical-stage biotech booked precisely zero revenue from customers, posted a net loss of $38.3m, and burned $41m of operating cash while handing shareholders a diluted loss per share of $6.77. The company’s assets stood at $229.1m, liabilities at $49.2m, and equity at minus $523.7m, an accounting mood ring that flashes crimson long before any medicine reaches a pharmacy shelf. (source: Odyssey Therapeutics 10-Q for the quarter ended 31 March 2026, https://www.sec.gov/Archives/edgar/data/1882782/000119312526274290/odtx-20260331.htm)

Odyssey’s pipeline is a glossy parade of immunology targets-OD-001 gearing up for Phase 2b trials, OD-07656 presenting preclinical slides at the American College of Gastroenterology, and management promising to “transform the standard of care” in autoimmune diseases. Yet the only collaboration revenue recognised so far is $400k from Pfizer’s option exercise, tucked into a footnote like a shy tip at a bar. The company also took $6.5m upfront from J&J in 2024 for a nonexclusive licence and R&D services, but the cash collected hasn’t yet paid the burn rate that clocked in at $32.3m of R&D spend in the last quarter alone. (source: Odyssey Therapeutics pipeline page, https://odysseytx.com/pipeline/; Odyssey Therapeutics press release on ACG 2024, https://odysseytx.com/odyssey-therapeutics-to-present-new-data-on-its-clinical-stage-ripk2-scaffolding-inhibitor-od-07656-at-the-american-college-of-gastroenterology-acg-annual-scientific-meeting-2024/; SEC 10-Q for the quarter ended 31 March 2026, https://www.sec.gov/Archives/edgar/data/1882782/000119312526274290/odtx-20260331.htm)

The cash register isn’t exactly ringing. Odyssey’s balance sheet shows $35.7m of cash and equivalents at 31 March 2026, set against $49.2m of liabilities and a quarterly operating cash outflow of $41m. The company spent just $148k on property, plant and equipment, which is less surprising once you notice it has no marketed products and no revenue from sales. Diluted shares outstanding ticked up to 5.7m, and the GAAP loss per share came in at $6.77, a figure that would make even the most ardent biotech bull wince. (source: Odyssey Therapeutics 10-Q for the quarter ended 31 March 2026, https://www.sec.gov/Archives/edgar/data/1882782/000119312526274290/odtx-20260331.htm)

For a company that describes itself as seeking to “transform the standard of care,” the market mechanism is still the same old biotech math: burn cash, raise money, extend the runway, and hope the next data readout justifies the next round. The filings do not provide guidance, forecasts, or approved products, and the only concrete revenue numbers come from upfront licence fees and R&D reimbursements-$1m from Pfizer in 2023, $6.5m from J&J in 2024, and $400k recognised in Q1 2025. The pipeline slide decks are full of immunology jargon and patient-need promises, while the cash-flow statement is short on patients and long on red ink. (source: Odyssey Therapeutics SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1882782; Odyssey Therapeutics 10-Q for the quarter ended 31 March 2026, https://www.sec.gov/Archives/edgar/data/1882782/000119312526274290/odtx-20260331.htm)

The company’s headline from the latest 8-K is a corporate update rather than an earnings beat, and it leans on the promise that OD-001 will initiate Phase 2b monotherapy and Phase 2a combination trials in the second half of 2026, with data in the back half of 2027. Until then, the operating reality is a treadmill of investor presentations, licence fees, and quarterly cash burns that the balance sheet is funding at a steadily increasing share count. The slide decks may feature smiling patients and molecule cartoons, but the cash-flow statement features a very real negative sign. (source: Odyssey Therapeutics 8-K filed 23 June 2026, https://www.sec.gov/Archives/edgar/data/1882782/000119312526278581/odtx-20260623.htm)

If Odyssey ever files a product revenue line, it will be news; if it files another equity raise, it will be routine. The evidence in hand still shows a pre-revenue biotech whose primary product is investor presentations and whose secondary product is hope-both of which are cheaper to produce than drugs. The next catalyst with a dollar sign will be the first licence fee beyond $6.5m or the first approved therapy; the next catalyst with a clinical readout will be OD-001’s Phase 2b induction data in 2027. Until then, the balance sheet is the only place where anything tangible is accumulating. (source: Odyssey Therapeutics 10-Q for the quarter ended 31 March 2026, https://www.sec.gov/Archives/edgar/data/1882782/000119312526274290/odtx-20260331.htm; Odyssey Therapeutics pipeline page, https://odysseytx.com/pipeline/)